HRS 9432
Alternative Names: HRS-9432Latest Information Update: 24 May 2024
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Candidaemia; Invasive candidiasis
Most Recent Events
- 24 May 2024 Phase-II clinical trials in Candidaemia in China (IV) (NCT06194201)
- 24 May 2024 Phase-II clinical trials in Invasive candidiasis in China (IV) (NCT06194201)
- 08 Jan 2024 Jiangsu Hengrui Medicine plans a phase II trial for Candidemia or invasive candidiasis (IV) (NCT06194201)